These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 12421104

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.
    McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP, Casodex Early Prostate Cancer Trialists' Group.
    BJU Int; 2006 Feb; 97(2):247-54. PubMed ID: 16430622
    [Abstract] [Full Text] [Related]

  • 3. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme.
    Tyrrell CJ, Payne H, See WA, McLeod DG, Wirth MP, Iversen P, Armstrong J, Morris C, 'Casodex' Early Prostate Cancer Trialists Group.
    Radiother Oncol; 2005 Jul; 76(1):4-10. PubMed ID: 16145740
    [Abstract] [Full Text] [Related]

  • 4. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.
    Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, Chamberlain M, Carroll K, Melezinek I.
    J Urol; 2000 Nov; 164(5):1579-82. PubMed ID: 11025708
    [Abstract] [Full Text] [Related]

  • 5. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer.
    See WA, Tyrrell CJ, CASODEX Early Prostate Cancer Trialists' Group.
    J Cancer Res Clin Oncol; 2006 Aug; 132 Suppl 1():S7-16. PubMed ID: 16896884
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer.
    See W, Iversen P, Wirth M, McLeod D, Garside L, Morris T.
    Eur Urol; 2003 Nov; 44(5):512-7; discussion 517-8. PubMed ID: 14572747
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer.
    Wellington K, Keam SJ.
    Drugs; 2006 Nov; 66(6):837-50. PubMed ID: 16706554
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Bicalutamide monotherapy for early stage prostate cancer: an update.
    Iversen P.
    J Urol; 2003 Dec; 170(6 Pt 2):S48-52; discussion S52-4. PubMed ID: 14610410
    [Abstract] [Full Text] [Related]

  • 15. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer.
    Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, Chamberlain M, Webster A, Blackledge G.
    Eur Urol; 1998 Dec; 33(5):447-56. PubMed ID: 9643663
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.